Shattuck Labs, Inc.

Shattuck Labs, Inc.

STTKยทNASDAQ

$4.80

-1.4%
HealthcareBiotechnology

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$229.94M
EPS-0.7000
P/E Ratio-6.86
Earnings Date08/06/2026

No Dividend Yield Data

STTK has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

STTK has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

STTK has not reported any net dividends paid values in the available annual periods.

Shattuck Labs, Inc.

Shattuck Labs, Inc. Dividend History

STTK ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

STTK Dividend Payment History

STTK ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
sttk

Shattuck Labs, Inc. Payout Ratio Analysis

STTK ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-48.81M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.